{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T07:30:52Z","timestamp":1785742252231,"version":"3.56.0"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100005614","name":"Biogen Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005614","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","msard-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.msard.2023.105127","type":"journal-article","created":{"date-parts":[[2023,11,5]],"date-time":"2023-11-05T15:34:00Z","timestamp":1699198440000},"page":"105127","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Discontinuation of dimethyl fumarate in multiple sclerosis - a nationwide study"],"prefix":"10.1016","volume":"80","author":[{"given":"Malte","family":"Roar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amalie Rhode H\u00f8gh","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas Munksgaard","family":"Berg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgi","family":"Sirakov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morten","family":"Stilund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakob","family":"Sch\u00e4fer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rikke","family":"Ratzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jette","family":"Frederiksen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nasrin","family":"Asgari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Said Nasim","family":"Ashna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik Boye","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Kant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1sta","family":"The\u00f3dorsd\u00f3ttir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zsolt","family":"Illes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Finn","family":"Sellebjerg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melinda","family":"Magyari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise Mose","family":"Schlosser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hilde","family":"Nordborg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stig","family":"Wergeland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7682-2188","authenticated-orcid":false,"given":"Tobias","family":"Sejbaek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2023.105127_bib0012","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1002\/9780470114759.ch2","article-title":"Contingency Tables","author":"Agresti","year":"2007","journal-title":"An Introduction to Categorical Data Analysis"},{"issue":"1","key":"10.1016\/j.msard.2023.105127_bib0015","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s40120-019-00174-3","article-title":"A Retrospective Analysis of Real-World Discontinuation Rates with Delayed-Release Dimethyl Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis","volume":"9","author":"Allan","year":"2020","journal-title":"Neurol. Ther."},{"issue":"2","key":"10.1016\/j.msard.2023.105127_bib0022","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1097\/JNN.0000000000000495","article-title":"Nursing Management of Gastrointestinal Adverse Events Associated With Delayed-Release Dimethyl Fumarate: A Global Delphi Approach","volume":"52","author":"Campbell","year":"2020","journal-title":"J. Neurosci. Nurs."},{"issue":"10","key":"10.1016\/j.msard.2023.105127_bib0005","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1111\/ene.13692","article-title":"Early versus later treatment start in multiple sclerosis: a register-based cohort study","volume":"25","author":"Chalmer","year":"2018","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.msard.2023.105127_bib0026","volume":"2014","year":"2015"},{"issue":"2","key":"10.1016\/j.msard.2023.105127_bib0023","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s00228-017-2366-4","article-title":"Persistence with dimethyl fumarate in relapsing-remitting multiple sclerosis: a population-based cohort study","volume":"74","author":"Eriksson","year":"2018","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"12","key":"10.1016\/j.msard.2023.105127_bib0016","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1080\/03007995.2017.1380616","article-title":"Relapse outcomes, safety, and treatment patterns in patients diagnosed with relapsing-remitting multiple sclerosis and initiated on subcutaneous interferon \u03b2-1a or dimethyl fumarate: a real-world study","volume":"33","author":"Ernst","year":"2017","journal-title":"Curr. Med. Res. Opin."},{"issue":"2","key":"10.1016\/j.msard.2023.105127_bib0025","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s40120-015-0037-x","article-title":"Consensus Management of Gastrointestinal Events Associated with Delayed-Release Dimethyl Fumarate: A Delphi Study","volume":"4","author":"Theodore Phillips","year":"2015","journal-title":"Neurol. Ther."},{"issue":"1","key":"10.1016\/j.msard.2023.105127_bib0030","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1177\/1352458515579216","article-title":"Comparative analysis of first-year fingolimod and natalizumab drug discontinuation among Swedish patients with multiple sclerosis","volume":"22","author":"Frisell","year":"2016","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2023.105127_bib0024","doi-asserted-by":"crossref","DOI":"10.1177\/1756286418768775","article-title":"Incidence and mitigation of gastrointestinal events in patients with relapsing-remitting multiple sclerosis receiving delayed-release dimethyl fumarate: a German phase IV study (TOLERATE)","volume":"11","author":"Gold","year":"2018","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.msard.2023.105127_bib0013","doi-asserted-by":"crossref","DOI":"10.1177\/1756286420915005","article-title":"Safety and efficacy of delayed-release dimethyl fumarate in patients with relapsing-remitting multiple sclerosis: 9 years\u2019 follow-up of DEFINE, CONFIRM, and ENDORSE","volume":"13","author":"Gold","year":"2020","journal-title":"Ther. Adv. Neurol. Disord."},{"issue":"8","key":"10.1016\/j.msard.2023.105127_bib0004","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1136\/jnnp-2017-315907","article-title":"Excess mortality among patients with multiple sclerosis in Denmark has dropped significantly over the past six decades: a population based study","volume":"88","author":"Koch-Henriksen","year":"2017","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"6","key":"10.1016\/j.msard.2023.105127_bib0006","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1111\/ane.13301","article-title":"Medication adherence\/persistence among patients with active multiple sclerosis in Finland","volume":"142","author":"Lahdenper\u00e4","year":"2020","journal-title":"Acta Neurol. Scand."},{"issue":"7","key":"10.1016\/j.msard.2023.105127_bib0017","doi-asserted-by":"crossref","first-page":"e635","DOI":"10.1212\/WNL.0000000000007938","article-title":"Comparative effectiveness of teriflunomide vs dimethyl fumarate in multiple sclerosis","volume":"93","author":"Laplaud","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2023.105127_bib0028","article-title":"Dimethyl fumarate-associated lymphopenia: Risk factors and clinical significance","volume":"1","author":"Longbrake","year":"2015","journal-title":"Mult. Scler. J. Exp. Transl. Clin."},{"issue":"1","key":"10.1016\/j.msard.2023.105127_bib0003","doi-asserted-by":"crossref","first-page":"e01921","DOI":"10.1002\/brb3.1921","article-title":"The Danish Multiple Sclerosis Registry","volume":"11","author":"Magyari","year":"2021","journal-title":"Brain Behav."},{"issue":"8","key":"10.1016\/j.msard.2023.105127_bib0018","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1007\/s00415-018-8916-6","article-title":"Two-year real-life efficacy, tolerability and safety of dimethyl fumarate in an Italian multicentre study","volume":"265","author":"Mallucci","year":"2018","journal-title":"J. Neurol."},{"issue":"1 Suppl A","key":"10.1016\/j.msard.2023.105127_bib0007","first-page":"S24","article-title":"Narrative review of the literature on adherence to disease-modifying therapies among patients with multiple sclerosis","volume":"19","author":"Menzin","year":"2013","journal-title":"J. Manag. Care Pharm."},{"issue":"10","key":"10.1016\/j.msard.2023.105127_bib0027","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1007\/s40263-018-0543-3","article-title":"Safety and Efficacy of Dimethyl Fumarate in Multiple Sclerosis: An Italian, Multicenter, Real-World Study","volume":"32","author":"Mirabella","year":"2018","journal-title":"CNS Drugs"},{"key":"10.1016\/j.msard.2023.105127_bib0001","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/B978-0-444-52898-8.00006-9","article-title":"The epidemiology of the epilepsies","volume":"107","author":"Neligan","year":"2012","journal-title":"Handb. Clin. Neurol."},{"key":"10.1016\/j.msard.2023.105127_bib0029","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.104081","article-title":"Risk factors for development of lymphopenia in dimethyl fumarate-treated patients with multiple sclerosis","volume":"67","author":"Ravn","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2023.105127_bib0014","doi-asserted-by":"crossref","first-page":"149","DOI":"10.2147\/PPA.S284425","article-title":"Effectiveness of Dimethyl Fumarate in Real-World Clinical Practice and Strategy to Minimize Adverse Effects and Use of Healthcare Resources","volume":"15","author":"Rodr\u00edguez-Regal","year":"2021","journal-title":"Patient Prefer Adherence"},{"issue":"8","key":"10.1016\/j.msard.2023.105127_bib0019","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.1007\/s00415-020-09848-7","article-title":"Tolerability and safety of dimethyl fumarate in relapsing multiple sclerosis: a prospective observational multicenter study in a real-life Spanish population","volume":"267","author":"Sabin","year":"2020","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2023.105127_bib0011","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.msard.2018.05.007","article-title":"Illes Z. Real-life persistence and tolerability with dimethyl fumarate","volume":"24","author":"Sejbaek","year":"2018","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2023.105127_bib0020","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.msard.2018.05.007","article-title":"Illes Z. Real-life persistence and tolerability with dimethyl fumarate","volume":"24","author":"Sejbaek","year":"2018","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"3","key":"10.1016\/j.msard.2023.105127_bib0002","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1111\/head.12074","article-title":"The prevalence, impact, and treatment of migraine and severe headaches in the United States: a review of statistics from national surveillance studies","volume":"53","author":"Smitherman","year":"2013","journal-title":"Headache"},{"issue":"2","key":"10.1016\/j.msard.2023.105127_bib0008","doi-asserted-by":"crossref","first-page":"89","DOI":"10.2165\/11533330-000000000-00000","article-title":"Impact of adherence to interferons in the treatment of multiple sclerosis: a non-experimental, retrospective, cohort study","volume":"30","author":"Steinberg","year":"2010","journal-title":"Clin. Drug Investig."},{"issue":"1","key":"10.1016\/j.msard.2023.105127_bib0009","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s12325-010-0093-7","article-title":"Impact of adherence to disease-modifying therapies on clinical and economic outcomes among patients with multiple sclerosis","volume":"28","author":"Tan","year":"2011","journal-title":"Adv. Ther."},{"issue":"5","key":"10.1016\/j.msard.2023.105127_bib0010","doi-asserted-by":"crossref","first-page":"497","DOI":"10.3111\/13696998.2015.1134546","article-title":"The impact of persistence with therapy on inpatient admissions and emergency room visits in the US among patients with multiple sclerosis","volume":"19","author":"Thomas","year":"2016","journal-title":"J. Med. Econ."},{"issue":"6","key":"10.1016\/j.msard.2023.105127_bib0021","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1177\/1756285616661929","article-title":"Efficacy and tolerability of dimethyl fumarate in White-, African- and Hispanic- Americans with multiple sclerosis","volume":"9","author":"Zhovtis Ryerson","year":"2016","journal-title":"Ther. Adv. Neurol. Disord."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034823006284?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034823006284?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,29]],"date-time":"2024-08-29T01:23:00Z","timestamp":1724894580000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034823006284"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":30,"alternative-id":["S2211034823006284"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2023.105127","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discontinuation of dimethyl fumarate in multiple sclerosis - a nationwide study","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2023.105127","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"105127"}}